In clinically node‑positive stage 3A (cT3a N1) bladder cancer, is radical cystectomy with extended pelvic lymph‑node dissection the preferred treatment?

Stage 3A Node-Positive Bladder Cancer: Radical Cystectomy with Extended Lymphadenectomy Following Neoadjuvant Chemotherapy is the Preferred Treatment

For clinically node-positive stage 3A (cT3a N1) bladder cancer, radical cystectomy with extended pelvic lymph node dissection preceded by neoadjuvant cisplatin-based chemotherapy is the preferred treatment approach, offering the best survival outcomes. 1

Primary Treatment Algorithm

Step 1: Neoadjuvant Chemotherapy (Strongly Recommended)

• Administer 3-4 cycles of cisplatin-based combination chemotherapy before surgery 1
• Preferred regimens include:
  • Gemcitabine plus cisplatin (category 1) 1
  • Dose-dense MVAC with growth factor support (category 1) 1
• This approach is based on evidence showing that patients with N1 disease benefit from aggressive multimodal treatment, with some achieving long-term survival or cure 1

Step 2: Radical Cystectomy with Extended Lymphadenectomy

• Perform radical cystectomy with bilateral extended pelvic lymph node dissection 1
• The lymphadenectomy must include at minimum: common iliac, internal iliac, external iliac, obturator, and sacral nodes 1
• Extended lymphadenectomy provides superior recurrence-free survival compared to limited dissection, particularly in node-positive disease (HR 0.58, P<0.001) 2
• Remove at least 15 pelvic lymph nodes, as this threshold is associated with improved overall survival in node-positive disease 3

Step 3: Adjuvant Therapy Consideration

• If neoadjuvant chemotherapy was not given, strongly consider adjuvant cisplatin-based chemotherapy (category 2B) 1
• Adjuvant chemotherapy improves disease-specific survival and overall survival in high-risk patients who did not receive neoadjuvant treatment 1

Evidence Supporting Surgery in Node-Positive Disease

The rationale for proceeding with radical cystectomy in clinically node-positive disease is supported by multiple lines of evidence:

• Pathologic downstaging occurs in 39% of cN1 patients who receive induction chemotherapy, compared to only 5% without chemotherapy 1
• A multi-institutional analysis of 304 patients with cN1-3 disease treated with induction chemotherapy followed by radical cystectomy showed a 48% pN0 rate and median overall survival of 22 months 3
• Long-term survival is achievable: 24-32% of patients with grossly node-positive disease can be cured with radical cystectomy and thorough lymph node dissection alone 4, 5
• A recent Veterans Health Administration study demonstrated that radical cystectomy was associated with improved overall survival (HR 0.62, P<0.001) and cancer-specific survival (HR 0.58, P<0.001) in node-positive disease 6

Bladder Preservation Alternative (Category 2B)

For highly selected patients who decline surgery or are medically unfit, bladder preservation with maximal TURBT followed by concurrent chemoradiotherapy may be considered 1:

• Optimal candidates must have: unifocal disease, no hydronephrosis, visibly complete or maximal TURBT achievable, and good performance status 7
• Deliver 64-66 Gy radiation with concurrent cisplatin-based chemotherapy 1
• Preferred radiosensitizing regimens: cisplatin/5-FU, cisplatin/paclitaxel, or 5-FU/mitomycin C 1

However, bladder preservation outcomes in node-positive disease are less well-established than for node-negative MIBC, and this approach should be reserved for patients who cannot undergo or refuse cystectomy 1.

Critical Pitfalls to Avoid

• Never substitute carboplatin for cisplatin in the perioperative setting, as carboplatin has not demonstrated survival benefit 1
• Do not give adjuvant chemotherapy if neoadjuvant chemotherapy was already administered 8
• Ensure adequate lymph node dissection: removing fewer than 15 nodes is associated with worse outcomes in node-positive disease 3
• Do not delay surgery excessively after neoadjuvant chemotherapy; proceed to cystectomy after 3-4 cycles if disease is stable or responding 1

Prognostic Factors

The best survival outcomes in node-positive disease are associated with:

• Complete pathologic nodal response (pN0) after neoadjuvant chemotherapy 3
• Negative surgical margins 3
• Removal of ≥15 pelvic lymph nodes 3
• Primary tumor confined to bladder (≤pT3a) rather than extravesical extension 4, 5

Patients with organ-confined primary tumors (≤pT2) and N1 disease have 5-year survival rates of 32-52%, compared to only 9.7-23% for those with extravesical (≥pT3b) tumors 4, 5.